Atlanta, GA — September 15, 2025 — Leads & Copy — GeoVax Labs, Inc. (Nasdaq: GOVX) presented positive interim results for its COVID-19 vaccine candidate, GEO-CM04S1, at the XXI International Workshop on Chronic Lymphocytic Leukemia (iwCLL 2025) in Krakow, Poland. The data comes from an ongoing Phase 2 trial (NCT05672355) comparing GEO-CM04S1 to a standard mRNA vaccine in chronic lymphocytic leukemia (CLL) patients.
The trial showed that GEO-CM04S1 met the statistical requirement to continue enrollment, while the mRNA vaccine did not. Enrollment has now shifted exclusively to the GEO-CM04S1 arm, following the recommendation of the Data Safety Monitoring Board. The company says the vaccine has a favorable safety profile, with no grade 3 or higher adverse events reported. According to GeoVax, CLL patients represent a high-need market where first-generation COVID-19 vaccines are often inadequate.
GEO-CM04S1 is a next-generation COVID-19 vaccine built on a Modified Vaccinia Ankara (MVA) vector, encoding both the Spike (S) and Nucleocapsid (N) proteins of SARS-CoV-2. It is currently in three Phase 2 clinical trials.
David Dodd, Chairman & CEO of GeoVax, stated that the data reinforces the value proposition of their multi-antigen MVA platform, demonstrating the ability to overcome the gap in protection for immunocompromised patients with CLL.
Company Contact:
info@geovax.com
678-384-7220
Media Contact:
Jessica Starman
media@geovax.com
Source: GeoVax Labs, Inc.
